{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:00:56Z","timestamp":1792461656841,"version":"4.5.0"},"reference-count":53,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Clinical trials showed that upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treatment of moderate-to-severe atopic dermatitis. However, daily practice studies are limited. This multicentre prospective study evaluated the effectiveness of 16 weeks of upadacitinib treatment for moderate-to-severe atopic dermatitis in adult patients, including those with previous inadequate response to dupilumab and\/or baricitinib, in daily practice. A total of 47 patients from the Dutch BioDay registry treated with upadacitinib were included. Patients were evaluated at baseline, and after 4, 8 and 16 weeks of treatment. Effectiveness was assessed by clinician- and patient-reported outcome measurements. Safety was assessed by adverse events and laboratory assessments. Overall, the probabilities (95% confidence intervals) of achieving Eczema Area and Severity Index \u2264\u20097 and Numerical Rating Scale \u2013 pruritus \u2264\u20094 were 73.0% (53.7\u201386.3) and 69.4% (48.7\u201384.4), respectively. The effectiveness of upadacitinib was comparable in patients with inadequate response to dupilumab and\/or baricitinib and in patients who were na\u00efve for these treatments or who had stopped such treatments due to adverse events. Fourteen (29.8%) patients discontinued upadacitinib due to ineffectiveness, adverse events or both (8.5%, 14.9% and 6.4%, respectively). Most frequently reported adverse events were acneiform eruptions (n\u2009=\u200910, 21.3%), herpes simplex (n\u2009=\u20096, 12.8%), nausea and airway infections (both n\u2009=\u20094, 8.5%). In conclusion, upadacitinib is an effective treatment for patients with moderate-to-severe atopic dermatitis, including those with previous inadequate response to dupilumab and\/or baricitinib treatment.\u00a0<\/jats:p>","DOI":"10.2340\/actadv.v103.5243","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T13:07:47Z","timestamp":1676552867000},"page":"adv00872","source":"Crossref","is-referenced-by-count":35,"title":["Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and\/or Baricitinib: Results from the BioDay Registry"],"prefix":"10.2340","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3371-6414","authenticated-orcid":false,"given":"Celeste M.","family":"Boesjes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7981-7771","authenticated-orcid":false,"given":"Liana F.","family":"Van der Gang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4441-1448","authenticated-orcid":false,"given":"Nicolaas P.A.","family":"Zuithoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0193-5794","authenticated-orcid":false,"given":"Daphne S.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7537-765X","authenticated-orcid":false,"given":"Lotte S.","family":"Spekhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Haeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1389-2971","authenticated-orcid":false,"given":"Marijke","family":"Kamsteeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9004-5111","authenticated-orcid":false,"given":"Marlies","family":"De Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-6993","authenticated-orcid":false,"given":"Marjolein S.","family":"De Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"26234","doi-asserted-by":"crossref","unstructured":"Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387: 1109-1122.","DOI":"10.1016\/S0140-6736(15)00149-X"},{"key":"26235","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(15)00149-X","DOI":"10.1016\/S0140-6736(15)00149-X"},{"key":"26236","doi-asserted-by":"crossref","unstructured":"Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy 2018; 73: 1284-1293.","DOI":"10.1111\/all.13401"},{"key":"26237","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/all.13401","DOI":"10.1111\/all.13401"},{"key":"26238","doi-asserted-by":"crossref","unstructured":"Pereyra-Rodriguez JJ, Alcantara-Luna S, Dominguez-Cruz J, Galan-Gutierrez M, Ruiz-Villaverde R, Vilar-Palomo S, et al. Short-term effectiveness and safety of biologics and small molecule drugs for moderate to severe atopic dermatitis: a systematic review and network meta-analysis. Life 2021; 11: 927.","DOI":"10.3390\/life11090927"},{"key":"26239","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/life11090927","DOI":"10.3390\/life11090927"},{"key":"26240","unstructured":"Domaingroup Allergy and Eczema and Association for Atopic Dermatitis (VMCE), the Netherlands. Dupilumab (opinion). Published April 2018 [accessed August 4, 2022]. Available from https:\/\/nvdv.nl\/professionals\/nvdv\/standpunten-en-leidraden\/introductie-van-dupilumab-voor-ernstig-constitutioneel-eczeem-ce-standpunt"},{"key":"26241","doi-asserted-by":"crossref","unstructured":"Miniotti M, Lazzarin G, Ortoncelli M, Mastorino L, Ribero S, Leombruni P. Impact on health-related quality of life and symptoms of anxiety and depression after 32 weeks of dupilumab treatment for moderate-to-severe atopic dermatitis. Dermatol Ther 2022; 35: e15407.","DOI":"10.1111\/dth.15407"},{"key":"26242","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.15407","DOI":"10.1111\/dth.15407"},{"key":"26243","unstructured":"Domaingroup Allergy and Eczema and Association for Atopic Dermatitis (VMCE), the Netherlands. Baricitinib (opinion). Published December 2020 [accessed August 4, 2022]. Available from https:\/\/nvdv.nl\/professionals\/nvdv\/standpunten-en-leidraden\/baricitinib-standpunt"},{"key":"26244","doi-asserted-by":"crossref","unstructured":"He Helen, Guttman-Yasky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Derm 2019; 20: 181-192.","DOI":"10.1007\/s40257-018-0413-2"},{"key":"26245","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-018-0413-2","DOI":"10.1007\/s40257-018-0413-2"},{"key":"26246","unstructured":"Domaingroup Allergy and Eczema and Association for Atopic Dermatitis (VMCE), the Netherlands. Upadacitinib (opinion). Published October 2021 [accessed August 4, 2022] Available from https:\/\/nvdv.nl\/nvdv\/standpunten-en-leidraden\/upadacitinib-standpunt"},{"key":"26247","doi-asserted-by":"crossref","unstructured":"Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs in Context 2020; 9: 5-8.","DOI":"10.7573\/dic.2020-8-5"},{"key":"26248","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.7573\/dic.2020-8-5","DOI":"10.7573\/dic.2020-8-5"},{"key":"26249","doi-asserted-by":"crossref","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021; 397: 2151-2168.","DOI":"10.1016\/S0140-6736(21)00588-2"},{"key":"26250","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(21)00588-2","DOI":"10.1016\/S0140-6736(21)00588-2"},{"key":"26251","doi-asserted-by":"crossref","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397: 2169-2218.","DOI":"10.1016\/S0140-6736(21)00589-4"},{"key":"26252","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(21)00589-4","DOI":"10.1016\/S0140-6736(21)00589-4"},{"key":"26253","doi-asserted-by":"crossref","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, de Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis a randomized clinical trial. JAMA 2021; 157: 1047-1055.","DOI":"10.1001\/jamadermatol.2021.3023"},{"key":"26254","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.3023","DOI":"10.1001\/jamadermatol.2021.3023"},{"key":"26255","doi-asserted-by":"crossref","unstructured":"Napolitano N, Fabbrocini G, Genco L, Martora F, Potestio L, Patruno C. Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience. J Eur Acad Dermatol Venereol 2022; 36: 1497-1498.","DOI":"10.1111\/jdv.18137"},{"key":"26256","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.18137","DOI":"10.1111\/jdv.18137"},{"key":"26257","doi-asserted-by":"crossref","unstructured":"Feraru G, Nevet MJ, Samuelov L, Hodak E, Avitan-Hersh E, Ziv M, et al. Real-life experience of upadacitinib for the treatment of adult patients with moderate-to-severe atopic dermatitis - a case series. J Eur Acad Dermatol Venereol 2022; 36: e832-e833.","DOI":"10.1111\/jdv.18311"},{"key":"26258","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.18311","DOI":"10.1111\/jdv.18311"},{"key":"26259","doi-asserted-by":"crossref","unstructured":"Pereyra-Rodriguez JJ, Herranz P, Figueras-Nart I, Perez B, Elosua M, Munera-Campos M, et al. Treatment of severe atopic dermatitis with upadacitinib in real clinical practice. Short-term efficacy and safety results. J Investig Allergol Clin Immunol 2022; Jun 2. [Online ahead of print].","DOI":"10.18176\/jiaci.0831"},{"key":"26260","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.18176\/jiaci.0831","DOI":"10.18176\/jiaci.0831"},{"key":"26261","doi-asserted-by":"crossref","unstructured":"Chiricozzi A, Gori N, Narcisi A, Balato A, Gambardella A, Ortoncelli M, et al. Effectiveness and safety of upadacitinib in the treatment of moderate\u2011severe atopic dermatitis: a multicentric, prospective, real\u2011world, cohort study. Drugs in R&D 2022; 22: 245-252.","DOI":"10.1007\/s40268-022-00396-1"},{"key":"26262","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40268-022-00396-1","DOI":"10.1007\/s40268-022-00396-1"},{"key":"26263","doi-asserted-by":"crossref","unstructured":"Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol 2015; 172: 1353-1357.","DOI":"10.1111\/bjd.13662"},{"key":"26264","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.13662","DOI":"10.1111\/bjd.13662"},{"key":"26265","doi-asserted-by":"crossref","unstructured":"Futamara M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. JAAD 2016; 74: 288-294.","DOI":"10.1016\/j.jaad.2015.09.062"},{"key":"26266","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2015.09.062","DOI":"10.1016\/j.jaad.2015.09.062"},{"key":"26267","doi-asserted-by":"crossref","unstructured":"Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012; 92: 502-507.","DOI":"10.2340\/00015555-1246"},{"key":"26268","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-1246","DOI":"10.2340\/00015555-1246"},{"key":"26269","doi-asserted-by":"crossref","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"26270","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"26271","doi-asserted-by":"crossref","unstructured":"Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol 2004; 140: 1513-1519.","DOI":"10.1001\/archderm.140.12.1513"},{"key":"26272","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/archderm.140.12.1513","DOI":"10.1001\/archderm.140.12.1513"},{"key":"26273","doi-asserted-by":"crossref","unstructured":"Griffiths C, de Bruin-Weller M, Deleuran M, Concetta Fargnoli M, Staumont-Sall\u00e9 D, et al. Dupilumab in adults with moderate-to-severe atopic dermatitis and prior use of systemic non-steroidal immunosuppressants: analysis of four phase 3 trials. Dermatol Ther 2021; 11: 1357-1372.","DOI":"10.1007\/s13555-021-00558-0"},{"key":"26274","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-021-00558-0","DOI":"10.1007\/s13555-021-00558-0"},{"key":"26275","doi-asserted-by":"crossref","unstructured":"Pariser DM, Simpson EL, Gadkari A, Bieber T, Margolis DJ, Brown M, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin 2020; 36: 367-376.","DOI":"10.1080\/03007995.2019.1699516"},{"key":"26276","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/03007995.2019.1699516","DOI":"10.1080\/03007995.2019.1699516"},{"key":"26277","doi-asserted-by":"crossref","unstructured":"De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: an International Consensus on a set of core decision points for systemic therapies. Acta Derm Venereol 2021; 17: 101-102.","DOI":"10.2340\/00015555-3751"},{"key":"26278","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3751","DOI":"10.2340\/00015555-3751"},{"key":"26279","doi-asserted-by":"crossref","unstructured":"Donders ART, Van der Heijden GJMG, Stijnen T, Moons KGM. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006; 59: 1087-1091.","DOI":"10.1016\/j.jclinepi.2006.01.014"},{"key":"26280","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jclinepi.2006.01.014","DOI":"10.1016\/j.jclinepi.2006.01.014"},{"key":"26281","doi-asserted-by":"crossref","unstructured":"Graham JW, Olchowski AE, Gilreath TD. How many imputations are really needed? Some practical clarifications of multiple imputation theory. Prev Sci 2007; 8: 206-213.","DOI":"10.1007\/s11121-007-0070-9"},{"key":"26282","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s11121-007-0070-9","DOI":"10.1007\/s11121-007-0070-9"},{"key":"26283","unstructured":"Robitzsch A, Grund S. Miceadds: Some Additional Multiple Imputation Functions, Especially for 'mice'. R package version 3.13-1. 2022. [Accessed 17 August 2022] Available from: https:\/\/cran.r-project.org\/web\/packages\/miceadds\/index.html."},{"key":"26284","unstructured":"RStudio Team. RStudio: Integrated Development for R. RStudio, PBC, Boston, MA. 2020. [Accessed 17 August 2022] Available from: URL:http:\/\/www.rstudio.com\/."},{"key":"26285","doi-asserted-by":"crossref","unstructured":"Guttman-Yassky E, Thyssen JP, Silverberg JI, Papp KA, Paller AS, Weidinger S, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies. J Allergy Clin Immunol 2023; 151: 172-181.","DOI":"10.1016\/j.jaci.2022.09.023"},{"key":"26286","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2022.09.023","DOI":"10.1016\/j.jaci.2022.09.023"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/5243\/13210","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/5243\/13210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T13:08:10Z","timestamp":1676552890000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/5243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":53,"URL":"https:\/\/doi.org\/10.2340\/actadv.v103.5243","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,16]]}}}